Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-751 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | Pemetrexed + ABT-751 |
| B | PLACEBO_COMPARATOR | Pemetrexed + placebo |
| Name | Type | Description |
|---|---|---|
| ABT-751 | DRUG | 200 mg ABT-751 daily for 14 days every 21 days |
| pemetrexed | DRUG | Standard pemetrexed every 21 days |
| placebo | DRUG | Placebo daily for 14 days every 21 days |
Inclusion Criteria: * Pathologically documented NSCLC * Locally advanced (Stage III) or metastatic (Stage IV) NSCLC * Only one prior anti-tumor treatment regimen in the non-curative setting (i.e., 2nd-line therapy) * Only one prior anti-tumor treatment regimen in the curative setting * Progressive ...
Top 20 of 76 competitors
ABT-751 is an investigational small molecule being studied for the treatment of lung cancer, specifically non-small cell lung cancer (NSCLC). It is being developed by AbbVie Inc. (NYSE: ABBV) and is currently in Phase 1 clinical development.
The specific molecular target of ABT-751 is not disclosed in the available information. It is a small molecule oncology drug being evaluated for its potential in treating lung cancer, but its mechanism of action has not been publicly detailed.
ABT-751 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The drug is an investigational small molecule in Phase 1 clinical development for lung cancer.
ABT-751 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One clinical trial has been completed, and no active trials are currently listed.
ABT-751 has been studied in one completed clinical trial, NCT00297089, a Phase 1/2 study evaluating ABT-751 in combination with Alimta in advanced non-small cell lung cancer. The trial enrolled 165 participants across the United States, Czechia, Greece, Hungary, Netherlands, and Slovakia.
No, ABT-751 is not the same as Alimta. Alimta (pemetrexed) is a separate chemotherapy drug that was used in combination with ABT-751 in the clinical trial NCT00297089. ABT-751 is an investigational small molecule being developed by AbbVie for lung cancer.